-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, O3uOPKwbAasoFVAWQIkhSZYLZB9lkkJk1nNZhDxJ65m2rZn+KwyT6jDjxzF5kokf K1enN6sb9opDWLClULYgIA== 0000950135-98-004161.txt : 19980703 0000950135-98-004161.hdr.sgml : 19980703 ACCESSION NUMBER: 0000950135-98-004161 CONFORMED SUBMISSION TYPE: 10-K/A PUBLIC DOCUMENT COUNT: 3 CONFORMED PERIOD OF REPORT: 19971231 FILED AS OF DATE: 19980702 SROS: NASD FILER: COMPANY DATA: COMPANY CONFORMED NAME: BIOGEN INC CENTRAL INDEX KEY: 0000714655 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 043002117 STATE OF INCORPORATION: MA FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-K/A SEC ACT: SEC FILE NUMBER: 000-12042 FILM NUMBER: 98660140 BUSINESS ADDRESS: STREET 1: 14 CAMBRIDGE CTR CITY: CAMBRIDGE STATE: MA ZIP: 02142 BUSINESS PHONE: 6176792000 MAIL ADDRESS: STREET 1: 14 CAMBRIDGE CTR CITY: CAMBRIDGE STATE: MA ZIP: 02142 FORMER COMPANY: FORMER CONFORMED NAME: BIOGEN NV DATE OF NAME CHANGE: 19880622 10-K/A 1 BIOGEN, INC. 1 FORM 10-K/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 (Mark One) [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 1997 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 0-12042 BIOGEN, INC. (Exact name of Registrant as specified in its charter) Massachusetts 04-3002117 (State or other jurisdiction (I.R.S. Employer of incorporation or organization) Identification No.) 14 Cambridge Center, Cambridge, Massachusetts 02142 (Address of principal executive offices)(zip code) Registrant's telephone number, including area code: (617) 679-2000 Securities registered pursuant to Section 12(b) of the Act: None Securities registered pursuant to Section 12(g) of the Act: Common Stock, $.01 par value (Title of class) Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes X No --- --- Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein, and will not be contained, to the best of Registrant's knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K. [ ] Aggregate market value of Common Stock held by nonaffiliates of the Registrant at February 18, 1998: $3,132,883,164 (excludes shares held by directors). Exclusion of shares held by any person should not be construed to indicate that such person possesses the power, direct or indirect, to direct or cause the direction of management or policies of the Registrant, or that such person is controlled by or under common control with the Registrant. Common Stock outstanding at February 18, 1998: 73,822,242 shares. 2 PART IV - ------- ITEM 14. EXHIBITS, FINANCIAL STATEMENT SCHEDULES, AND REPORTS ON FORM 8-K (3) Exhibits Exhibit No. Description - ----------- ----------- (23) Consent of Price Waterhouse LLP (99.1) Financial Statements for Biogen Savings Plan 3 Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. BIOGEN, INC. By: /s/ Michael J. Astrue ------------------------------ Michael J. Astrue Vice President - General Counsel Dated June 30, 1998 4 EXHIBIT INDEX Exhibit No. Description - ----------- ----------- (23) Consent of Price Waterhouse LLP (99.1) Financial Statements for Biogen Savings Plan EX-23 2 CONSENT OF PRICE WATERHOUSE LLP 1 CONSENT OF INDEPENDENT ACCOUNTANTS We hereby consent to the incorporation by reference in the Registration Statement on Form S-8 of Biogen Savings Plan of our report dated May 28, 1998 relating to the financial statements of the Biogen Savings Plan for the year ended December 31, 1997 included with this Form 10-K/A. PRICE WATERHOUSE LLP Boston, Massachusetts June 30, 1998 EX-99.1 3 FINANCIAL STATEMENTS FOR BIOGEN SAVINGS PLAN 1 BIOGEN, INC. BIOGEN SAVINGS PLAN FINANCIAL STATEMENTS AND SUPPLEMENTAL SCHEDULES DECEMBER 31, 1997 AND 1996 2 BIOGEN, INC. BIOGEN SAVINGS PLAN INDEX TO FINANCIAL STATEMENTS AND SUPPLEMENTAL SCHEDULES - -------------------------------------------------------------------------------- PAGE Report of Independent Accountants 1-2 Statement of Assets Available for Plan Benefits as 3 of December 31, 1997 and 1996 Statements of Changes in Assets Available for Plan 4-5 Benefits (with Fund Information) for the Year Ended December 31, 1997 Notes to Financial Statements 6-9 Supplemental Schedules*: Supplemental Schedule I Assets Held for Investment as of December 31, 1997 10 Supplemental Schedule II Transactions Involving Amounts in Excess of 5% 11 of the Current Value of Plan Assets for the Year Ended December 31, 1997 * Other schedules have been omitted because such schedules are not applicable. 3 REPORT OF INDEPENDENT ACCOUNTANTS May 28, 1998 To the Participants and Administrator of the Biogen Savings Plan We have audited the accompanying statement of assets available for benefits of the Biogen Savings Plan (the "Plan") as of December 31, 1997 and 1996 and the related statement of changes in assets available for benefits for the year ended December 31, 1997. These financial statements are the responsibility of the Plan's management. Our responsibility is to express an opinion on these financial statements based on our audits. We conducted our audits in accordance with generally accepted auditing standards. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion. In our report dated July 30, 1997, we were unable to, and did not, express an opinion on the 1996 financial statements because, at the instruction of the plan administrator, we did not perform any auditing procedures with respect to the information summarized in Note 4 in those financial statements. In conjunction with our audit of the 1997 financial statements, the plan administrator instructed us to perform, and we did perform, an audit of the 1996 financial statements in accordance with generally accepted auditing standards. Accordingly, we are now able to express an opinion on the 1996 financial statements. In our opinion, the financial statements referred to in the first paragraph of this report present fairly, in all material respects, the assets available for benefits of the Plan as of December 31, 1997 and 1996, and the changes in assets available for benefits for the year ended December 31, 1997 in conformity with generally accepted accounting principles. 4 To the Participants and Administrator of the Biogen Savings Plan Page 2 May 28, 1998 Our audits were made for the purpose of forming an opinion on the basic financial statements taken as a whole. The additional information included in Schedules I and II is presented for purposes of additional analysis and is not a required part of the basic financial statements but is additional information required by ERISA. The Fund Information in the statement of changes in assets available for benefits is presented for purposes of additional analysis rather than to present the changes in assets available for benefits of each fund. Schedules I and II and the Fund Information have been subjected to the auditing procedures applied in the audits of the basic financial statements and, in our opinion, are fairly stated in all material respects in relation to the basic financial statements taken as a whole. Price Waterhouse LLP 5 BIOGEN, INC. BIOGEN SAVINGS PLAN STATEMENT OF ASSETS AVAILABLE FOR PLAN BENEFITS - --------------------------------------------------------------------------------
DECEMBER 31, 1997 1996 ASSETS Investments at fair value: Mutual funds: Fidelity Intermediate Bond Fund $ 1,184,786 $ 1,105,700 Fidelity Puritan Fund 4,591,063 3,309,133 Fidelity Value Fund 774,097 83,349 Fidelity Magellan Fund 6,867,334 5,329,214 Fidelity Retirement Government Money Market Fund 1,525,381 1,244,690 Fidelity Growth Company Fund 5,751,258 4,642,871 Fidelity International Growth Income Fund 455,993 432,688 Fidelity Asset Manager Fund 663,018 356,645 Fidelity US Equity Index Fund 1,679,043 729,995 Fidelity US Bond Index Fund 197,146 39,852 Fidelity Low Priced Stock Fund 111,518 - USAA International Fund 20,983 - Janus Worldwide Fund 170,532 - ----------- ----------- Total mutual funds 23,992,152 17,274,137 ----------- ----------- Biogen, Inc. common stock 3,486,508 3,528,552 Interest bearing cash 77,153 - ----------- ----------- Total Biogen, Inc. stock fund 3,563,661 3,528,552 Loans to participants 707,329 474,929 ----------- ----------- Total investments 28,263,142 21,277,618 ----------- ----------- Assets available for plan benefits $28,263,142 $21,277,618 =========== ===========
The accompanying notes are an integral part of the financial statements. 3 6 BIOGEN, INC. BIOGEN SAVINGS PLAN STATEMENT OF CHANGES IN ASSETS AVAILABLE FOR PLAN BENEFITS (WITH FUND INFORMATION) - --------------------------------------------------------------------------------
YEAR ENDED DECEMBER 31, 1997 PARTICIPANT DIRECTED -------------------------------------------------------------------------------------- FIDELITY RETIREMENT FIDELITY FIDELITY FIDELITY FIDELITY FIDELITY GOVERNMENT GROWTH INTERMEDIATE PURITAN VALUE MAGELLAN MONEY MARKET COMPANY BOND FUND FUND FUND FUND FUND FUND ADDITIONS Contributions: Employee $ 136,470 $ 636,147 $108,506 $ 854,609 $ 116,702 $ 956,584 Rollover 89,268 134,265 94,989 179,750 150,629 142,438 Employer - - - - - - ---------- ---------- -------- ---------- ---------- ---------- Total contributions 225,738 770,412 203,495 1,034,359 267,331 1,099,022 Net appreciation (depreciation) of investments: Mutual funds 9,109 428,934 (16,488) 995,802 - 338,019 Biogen, Inc. common stock - - - - - - Interest and dividend income 67,233 357,612 101,824 441,449 75,119 544,275 Other loan repayment 10,654 79,695 332 114,767 8,271 77,331 ---------- ---------- -------- ---------- ---------- ---------- Total additions 312,734 1,636,653 289,163 2,586,377 350,721 2,058,647 DEDUCTIONS Distributions to participants (111,084) (258,837) (13,422) (512,085) (74,065) (339,838) ---------- ---------- -------- ---------- ---------- ---------- Net increase (decrease) prior to interfund transfers and loans 201,650 1,377,816 275,741 2,074,292 276,656 1,718,809 Interfund transfers and loans (122,564) (95,886) 415,007 (536,172) 4,035 (610,422) ---------- ---------- -------- ---------- ---------- ---------- Net increase (decrease) 79,086 1,281,930 690,748 1,538,120 280,691 1,108,387 Assets available for plan benefits, beginning of year 1,105,700 3,309,133 83,349 5,329,214 1,244,690 4,642,871 ---------- ---------- -------- ---------- ---------- ---------- Assets available for plan benefits, end of year $1,184,786 $4,591,063 $774,097 $6,867,334 $1,525,381 $5,751,258 ========== ========== ======== ========== ========== ==========
YEAR ENDED DECEMBER 31, 1997 PARTICIPANT DIRECTED --------------------------------------------- FIDELITY FIDELITY FIDELITY INTERNATIONAL ASSET U.S. EQUITY GROWTH MANAGER INDEX INCOME FUND FUND FUND ADDITIONS Contributions: Employee $176,161 $130,312 $ 276,459 Rollover 71,025 57,876 86,356 Employer - - - -------- -------- ---------- Total contributions 247,186 188,188 362,815 Net appreciation (depreciation) of investments: Mutual funds 2,593 51,161 317,955 Biogen, Inc. common stock - - - Interest and dividend income 28,757 67,843 33,173 Other loan repayment 4,852 6,162 3,228 -------- -------- ---------- Total additions 283,388 313,354 717,171 DEDUCTIONS Distributions to participants (40,615) (30,546) (42,721) -------- -------- ---------- Net increase (decrease) prior to interfund transfers and loans 242,773 282,808 674,450 Interfund transfers and loans (219,468) 23,565 274,598 -------- -------- ---------- Net increase (decrease) 23,305 306,373 949,048 Assets available for plan benefits, beginning of year 432,688 356,645 729,995 -------- -------- ---------- Assets available for plan benefits, end of year $455,993 $663,018 $1,679,043 ======== ======== ==========
The accompanying notes are an integral part of these financial statements. 4 7 BIOGEN, INC. BIOGEN SAVINGS PLAN STATEMENT OF CHANGES IN ASSETS AVAILABLE FOR PLAN BENEFITS (WITH FUND INFORMATION) (CONTINUED) - --------------------------------------------------------------------------------
YEAR ENDED DECEMBER 31, 1997 PARTICIPANT DIRECTED ------------------------------------------------------------------ FIDELITY FIDELITY U.S. LOW-PRICED USAA JANUS BOND INDEX STOCK INTERNATIONAL WORLDWIDE LOAN FUND FUND FUND FUND FUND ADDITIONS Contributions: Employee $ 32,752 $ 2,274 $ 258 $ 4,278 $ - Rollover 43,062 6,009 - 6,509 - Employer - - - - - -------- -------- -------- -------- -------- Total contributions 75,814 8,283 258 10,787 - Net appreciation (depreciation) of investments: Mutual funds 3,680 451 (880) (9,828) - Biogen, Inc. common stock - - - - - Interest and dividend income 7,855 913 1,081 11,616 - Other loan repayment 551 - - - (257,280) -------- -------- -------- -------- -------- Total additions 87,900 9,647 459 12,575 (257,280) DEDUCTIONS Distributions to participants (13,167) - - - (14,714) -------- -------- -------- -------- -------- Net increase (decrease) prior to interfund transfers and loans 74,733 9,647 459 12,575 (271,994) Interfund transfers and loans 82,561 101,871 20,524 157,957 504,394 -------- -------- -------- -------- -------- Net increase (decrease) 157,294 111,518 20,983 170,532 232,400 Assets available for plan benefits, beginning of year 39,852 - - - 474,929 -------- -------- -------- -------- -------- Assets available for plan benefits, end of year $197,146 $111,518 $ 20,983 $170,532 $707,329 ======== ======== ======== ======== ========
YEAR ENDED DECEMBER 31, 1997 NON-PARTICIPANT DIRECTED ---------------------------- BIOGEN, INC. BIOGEN, INC. STOCK FUND STOCK TOTAL ADDITIONS Contributions: Employee $ - $ - $ 3,431,512 Rollover - - 1,062,176 Employer 8,075 474,305 482,380 ---------- ----------- ----------- Total contributions 8,075 474,305 4,976,068 Net appreciation (depreciation) of investments: Mutual funds - - 2,120,508 Biogen, Inc. common stock 85,697 (315,390) (229,693) Interest and dividend income - 700 1,739,450 Other loan repayment - - 48,563 ---------- ----------- ----------- Total additions 93,772 159,615 8,654,896 DEDUCTIONS Distributions to participants - (218,278) (1,669,372) ---------- ----------- ----------- Net increase (decrease) prior to interfund transfers and loans 93,772 (58,663) 6,985,524 Interfund transfers and loans 3,469,889 (3,469,889) - ---------- ----------- ----------- Net increase (decrease) 3,563,661 (3,528,552) 6,985,524 Assets available for plan benefits, beginning of year - 3,528,552 21,277,618 ---------- ----------- ----------- Assets available for plan benefits, end of year $3,563,661 $ - $28,263,142 ========== =========== ===========
The accompanying notes are an integral part of these financial statements. 5 8 BIOGEN, INC. BIOGEN SAVINGS PLAN NOTES TO FINANCIAL STATEMENTS - -------------------------------------------------------------------------------- 1. DESCRIPTION OF THE PLAN The following brief description of the Biogen Savings Plan (the "Plan") is provided for general information purposes only. Participants should refer to the Plan agreement for more complete information. GENERAL INFORMATION Biogen, Inc. (the "Company") established the Plan as a deferred profit-sharing plan under Section 401(a) of the Internal Revenue Code of 1986, effective January 1, 1987. The Plan is designed to allow eligible employees to accumulate savings for retirement in the Plan without paying income taxes until the savings are actually received. ADMINISTRATION OF THE PLAN The Plan is administered by the Savings Plan Committee (the "Plan Committee"), whose members are appointed by the Company. Fidelity Management Trust Company is the Plan trustee (the "Trustee"). Administrative costs of the Plan have been assumed by the Company. PARTICIPATION Participation in the Plan is voluntary. Each employee of the Company is eligible to participate in the Plan upon the attainment of age 21 unless he/she is (a) a student employed on a temporary basis, (b) an employee of a non-U.S. subsidiary or division of the Company, or (c) a member of a collective bargaining unit. CONTRIBUTIONS Eligible employees may make savings deposits to the Plan in whole percentages of their gross salary ranging from a minimum of 2% to a maximum of 18%, subject to certain limitations. For each pay period, the Company will make a matching contribution of units of the Biogen Inc., stock fund equal in value to 25% of each employee's savings deposit up to a maximum of 6% of the employee's gross salary, subject to certain limitations. INVESTMENT OF CONTRIBUTIONS Company matching contributions are invested in the Biogen, Inc. stock fund. Prior to December 5, 1997, the matching contribution was invested directly in Biogen, Inc. stock. On December 5, 1997 the amounts in the stock account were converted into units of the Biogen, Inc. stock fund which includes Biogen, Inc. stock and cash or short term investments. Employee contributions are invested at the direction of the employee in increments of 10% in any combination of the following investment options: o An intermediate bond fund designed to earn a high level of current return. It is invested in Fidelity's Intermediate Bond Fund. o A balanced fund designed to preserve principal balance by investing in a diversified portfolio of high yielding stocks and bonds. It is invested in Fidelity's Puritan Fund. o An aggressive growth fund invested which seeks to achieve capital appreciation. It is invested in Fidelity's Magellan Fund. o A US government money market fund seeks high current earnings while preserving capital and liquidity. It is invested in Fidelity's Retirement Government Money Market Fund. 6 9 BIOGEN, INC. BIOGEN SAVINGS PLAN NOTES TO FINANCIAL STATEMENTS - -------------------------------------------------------------------------------- o A growth company fund which seeks to provide capital appreciation from investments primarily in common stock of companies with above-average growth characteristics. It is invested in Fidelity's Growth Company Fund. o An international equity fund which seeks capital growth, current income and growth of income. It is invested in the Fidelity International Growth & Income Fund. o An asset allocation fund that seeks total return with reduced risk over the long term. It is invested in the Fidelity Asset Manager Fund. o A long term growth fund which seeks to provide investment results that correspond to the total return performance of common stock of companies publicly traded in the US. It is invested in the Fidelity US Equity Index Fund. o A corporate bond fund that seeks to replicate the price and interest performance of the debt securities in the Lehman Brothers Aggregate Bond Index. It is invested in the Fidelity US Bond Index Fund. o A fund which seeks to provide capital appreciation from investments in companies which are undervalued or which possess valuable fixed assets. It is invested in the Fidelity Value Fund. The Plan added the following investment options effective October 1, 1997: o A fund which seeks to provide capital appreciation from investments in companies which are undervalued or which are out of favor with other investors and that could offer the possibility for significant growth. It is invested in the Fidelity Low-Priced Stock Fund. o A fund that seeks capital growth over the long term from investments in common stocks of foreign and domestic companies. It is invested in the Janus Worldwide Fund. o A fund that seeks long term capital growth and current income from investments in stocks of companies organized and operating principally outside the United States. It is invested in the USAA International Fund. The Plan added the following investment option effective January 1, 1998. o A fund that pools money to buy shares of Biogen, Inc. stock and cash or short-term investments. It is invested in the Biogen, Inc. stock fund. Note: Prior to January 1, 1998 only the employer match was invested in Biogen, Inc. stock. Dividends, interest, and other distributions received in any fund are reinvested in the same fund. VESTING Participants are fully vested in their savings deposit accounts and rollover accounts at all times. Participants will vest in the employer's matching contribution at a rate of 25% for each year of Plan service and will be fully vested after four years of Plan service. Participants become 100% vested in employer's matching contributions upon retirement or termination of employment due to disability. 7 10 BIOGEN, INC. BIOGEN SAVINGS PLAN NOTES TO FINANCIAL STATEMENTS - -------------------------------------------------------------------------------- WITHDRAWALS AND DISTRIBUTIONS Distributions are generally payable at termination of employment due to retirement, disability, death or any other reason. Distribution payments are made in cash in a lump sum for employees' contributions and in whole shares of stock for Company matching contributions. Forfeitures of nonvested amounts are used to reduce the amount of future Company matching contributions. LOANS Participants may borrow against their savings deposits. Loans will bear a reasonable interest rate determined by the Company. Repayment of loans is made by direct withholdings of a participant's salary for a period not to exceed five years (ten years for a residential loan). The minimum loan amount is $1,000 and a participant may borrow up to a maximum of 50% of the participant's vested account balance or $50,000, whichever is smaller. There is no minimum service requirement for a participant to be eligible for a loan. PLAN AMENDMENT AND TERMINATION The Company has the right to amend, suspend or terminate the Plan, but may not do so in a way which would divest a participant of accrued vested benefits. If the Plan is terminated, the Trustee will distribute the assets held in the trust, after payment of expenses, in such a manner as the Committee shall determine. The Company currently has no intention to terminate the Plan. 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts and disclosures in the financial statements. Actual results could differ from those estimates. The following is a summary of significant accounting policies which are in conformity with generally accepted accounting principles consistently followed by the Plan in the preparation of its financial statements. BASIS OF ACCOUNTING The financial statements of the Plan are prepared on the accrual basis of accounting. INVESTMENTS Plan investments are stated at fair value. The Company stock is valued at its quoted market price. Mutual fund investments are valued at net asset value representing the value of which shares of the fund may be purchased or redeemed. Loans to participants are stated at principal plus accrued interest, which approximates fair value. Purchases and sales of securities are recorded on a trade-date basis. Cost is determined on the average cost basis. Net appreciation or depreciation, which includes realized and unrealized gains or losses on investments, is reflected for the year in the statement of changes in assets available for plan benefits. 8 11 BIOGEN, INC. BIOGEN SAVINGS PLAN NOTES TO FINANCIAL STATEMENTS - -------------------------------------------------------------------------------- INCOME TAXES No provision for income taxes has been made in the financial statements as the Plan qualifies as a tax-exempt entity under Section 401 of the Internal Revenue Code ("Code"). The Plan has received a favorable determination letter dated June 5, 1996 from the Internal Revenue Service. The Plan has since been amended and a new letter has not been requested. Management has asserted the Plan, as amended, and its operations have been and continue to be in accordance with all applicable provisions of the Code and the Employee Retirement Income Security Act of 1974 ("ERISA"). 3. LOANS TO PARTICIPANTS At December 31, 1997 and 1996, the Plan had loans receivable from participants aggregating $707,329 and $474,929, respectively. Interest rates on the loans range from 7.0% to 11.0% annually. The loans are secured by the participant's interest in the Plan. 9 12 Biogen, Inc. Biogen Savings Plan Supplemental Schedule I Assets Held for Investment (Item 27a, Form 5500) December 31, 1997
NUMBER OF CURRENT SHARES/UNITS COST VALUE 116,498 Fidelity Intermediate Bond Fund $ 1,183,928 $ 1,184,786 236,897 Fidelity Puritan Fund 4,015,887 4,591,063 14,325 Fidelity Value Fund 798,388 774,097 72,083 Fidelity Magellan Fund 5,644,112 6,867,334 1,525,381 Fidelity Retirement Government Money Market Fund 1,525,381 1,525,381 132,762 Fidelity Growth Company Fund 4,816,266 5,751,258 23,147 Fidelity International Growth Income Fund 451,336 455,993 35,878 Fidelity Asset Manager Fund 611,005 663,018 48,000 Fidelity U.S. Equity Index Fund 1,329,321 1,679,043 18,271 Fidelity US Bond Index Fund 193,749 197,146 4,438 Fidelity Low Priced Stock Fund 111,067 111,518 1,091 USAA International Fund 21,814 20,983 4,514 Janus Worldwide Fund 180,360 170,532 ----------- ----------- Total mutual funds 20,882,614 23,992,152 ----------- ----------- 95,849 Biogen, Inc. common stock 1,988,270 3,486,508 77,153 Interest bearing cash 77,153 77,153 ----------- ----------- Total Biogen, Inc. stock fund 2,065,423 3,563,661 Loans to participants 707,329 707,329 ----------- ----------- Total $23,655,366 $28,263,142 =========== ===========
Page 10 13 Biogen, Inc. Biogen Savings Plan Supplemental Schedule II Transactions Involving Amounts in Excess of 5% of Current Value of Assets (Item 27d, Form 5500) Year Ended December 31, 1997
NUMBER OF PURCHASE SELLING LEASE PARTY INVOLVED DESCRIPTION OF ASSET TRANSACTIONS PRICE PRICE RENTAL Fidelity Management Fidelity Puritan Fund 126 $1,353,273 $ - $ - Trust Company 80 - 500,277 - Fidelity Management Fidelity Magellan Fund 137 1,700,001 - - Trust Company 95 - 1,157,682 - Fidelity Management Fidelity Growth Company 125 1,831,721 - - Trust Company 88 - 1,061,353 - Fidelity Management Fidelity US Equity Index 93 911,703 - - Trust Company 33 - 280,609 - Fidelity Management Fidelity Retirement Governme 76 691,848 - - Trust Company Money Market Fund 41 - 411,157 - Fidelity Management Biogen, Inc. stock 75 499,561 - - Trust Company 53 - 3,712,723 - Fidelity Management Biogen, Inc. stock fund 3 3,477,964 - - Trust Company CURRENT VALUE ON EXPENSE HISTORICAL TRANSACTION PARTY INVOLVED DESCRIPTION OF ASSET INCURRED COST DATE GAIN (LOSS) Fidelity Management Fidelity Puritan Fund $ - $ - $1,353,273 $ - Trust Company - 442,549 500,277 57,728 Fidelity Management Fidelity Magellan Fund - - 1,700,001 - Trust Company - 979,041 1,157,682 178,641 Fidelity Management Fidelity Growth Company - - 1,831,721 - Trust Company - 830,750 1,061,353 230,603 Fidelity Management Fidelity US Equity Index - - 911,703 - Trust Company - 236,510 280,609 44,099 Fidelity Management Fidelity Retirement Governme - 691,848 - Trust Company Money Market Fund 411,157 411,157 - Fidelity Management Biogen, Inc. stock - - 499,561 - Trust Company 3,598,915 3,712,723 113,808 Fidelity Management Biogen, Inc. stock fund - - 3,477,964 - Trust Company
Page 11 -----END PRIVACY-ENHANCED MESSAGE-----